This is an important victory not only for Pfizer but for all innovators pursuing high-risk medical discoveries.

The legal victory represents a significant reduction in the risk profile of the company. The company's fending off of this major threat is likely to lift sentiment for the entire large-cap pharmaceutical group through the remainder of 2005.

Fortunately, this happened in a strong economy, ... But I don't think anyone would say it will be positive.

We share some of your disappointment in some of the news reported today, ... Beyond the quarterly numbers, we ask you to look at the greater picture of a Pfizer in transition.

We are moving from what I call the 'old Pfizer,' a company characterized by the medicines we launched so successfully in the 1990s, to the 'next generation' Pfizer, characterized by a new wave of important medicines now reaching patients.

[The media] needs to inform the public without terrorizing the public. We're prepared to defend our products in the public domain.